We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Sloppy NDAs May Signal GMP Issues, Other Problems
FDA: Sloppy NDAs May Signal GMP Issues, Other Problems
November 2, 2009
Sloppy NDAs may be considered red flags by the FDA, prompting regulators to take a closer look at GMPs and other company processes, an agency official
says.